No profile data available.
Cel-sci Corporation (CVM) is a healthcare company in the additional cancer treatment drugs industry, based in Vienna, United States.
It reported revenue of $0 for fiscal year 2025, and net income of -$25.41 million. In Q2 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $34.12 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Cel-sci reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$34.12 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Adlai Nortye Ltd. (ANL), NextCure, Inc. (NXTC), Genenta Science S.p.A. (GNTA), TransCode Therapeutics, Inc. (RNAZ).